BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 472] [Article Influence: 63.3] [Reference Citation Analysis]
Number Citing Articles
1 Tapper EB, Afdhal NH. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol 2015;31:192-8. [PMID: 25730177 DOI: 10.1097/MOG.0000000000000169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
2 Baffy G. MicroRNAs in Nonalcoholic Fatty Liver Disease. J Clin Med. 2015;4:1977-1988. [PMID: 26690233 DOI: 10.3390/jcm4121953] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
3 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol 2016;111:658-64. [PMID: 27002796 DOI: 10.1038/ajg.2016.57] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
5 Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948-963. [PMID: 30819364 DOI: 10.1016/j.jacc.2018.11.050] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 80.0] [Reference Citation Analysis]
6 Dvorak K, Hainer R, Petrtyl J, Zeman M, Vareka T, Zak A, Sroubkova R, Svestka T, Vitek L, Bruha R. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:442-8. [PMID: 25004910 DOI: 10.5507/bp.2014.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 2014;34:e171-9. [PMID: 24575957 DOI: 10.1111/liv.12514] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 11.1] [Reference Citation Analysis]
9 Hakkak R, Bell A, Korourian S. Dehydroepiandrosterone (DHEA) Feeding Protects Liver Steatosis in Obese Breast Cancer Rat Model. Sci Pharm 2017;85:E13. [PMID: 28335515 DOI: 10.3390/scipharm85010013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Redman JS, Natarajan Y, Hou JK, Wang J, Hanif M, Feng H, Kramer JR, Desiderio R, Xu H, El-Serag HB, Kanwal F. Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Dig Dis Sci 2017;62:2713-8. [PMID: 28861720 DOI: 10.1007/s10620-017-4721-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
11 Mahabir S. Is nonalcoholic fatty liver disease driving the increased incidence of liver cancer?: Correspondence. Cancer 2016;122:2277-8. [DOI: 10.1002/cncr.30055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Rabinowich L, Shibolet O. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int 2015;2015:168905. [PMID: 26273591 DOI: 10.1155/2015/168905] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
13 Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 2015;21:1016-1021. [PMID: 25845711 DOI: 10.1002/lt.24134] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
14 Kozlitina J. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020;49:25-44. [PMID: 32033763 DOI: 10.1016/j.gtc.2019.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
15 Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One 2016;11:e0147237. [PMID: 26905872 DOI: 10.1371/journal.pone.0147237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
16 Hakkak R, Rose S, Spray B, Kozaczek M, Korourian S. Effects of obesity and 10 weeks metformin treatment on liver steatosis. Biomed Rep 2021;14:49. [PMID: 33859820 DOI: 10.3892/br.2021.1425] [Reference Citation Analysis]
17 Li Y, Zhang W, Doughtie A, Cui G, Li X, Pandit H, Yang Y, Li S, Martin R. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Oncotarget. 2016;7:52329-52339. [PMID: 27447573 DOI: 10.18632/oncotarget.10750] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
18 Loftfield E, Freedman ND, Lai GY, Weinstein SJ, McGlynn KA, Taylor PR, Männistö S, Albanes D, Stolzenberg-Solomon RZ. Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. Cancer Prev Res (Phila) 2016;9:866-74. [PMID: 27574287 DOI: 10.1158/1940-6207.CAPR-16-0141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
19 Oliveira CP, Stefano JT, Carrilho FJ. Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surg Nutr 2017;6:350-2. [PMID: 29152487 DOI: 10.21037/hbsn.2017.06.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Ha J, Chaudhri A, Avirineni A, Pan JJ. Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. Biomark Res 2017;5:15. [PMID: 28439416 DOI: 10.1186/s40364-017-0096-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Denova-Gutiérrez E, Lara-Castor L, Hernández-Alcaraz C, Hernández-Ávila M, Aguilar-Salinas C, Kershenobich D, Barquera S. Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016. Ann Hepatol 2021;:100562. [PMID: 34653686 DOI: 10.1016/j.aohep.2021.100562] [Reference Citation Analysis]
22 Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018;24:211-219. [PMID: 29956688 DOI: 10.4103/sjg.sjg_122_18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
23 Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (Baltimore) 2020;99:e23506. [PMID: 33327291 DOI: 10.1097/MD.0000000000023506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Phan H, Richard A, Lazo M, Nelson WG, Denmeade SR, Groopman J, Kanarek N, Platz EA, Rohrmann S. The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men. Liver Int 2021;41:300-10. [PMID: 32860311 DOI: 10.1111/liv.14652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Park SR, Cho CS, Xi J, Kang HM, Lee JH. Holistic characterization of single-hepatocyte transcriptome responses to high-fat diet. Am J Physiol Endocrinol Metab 2021;320:E244-58. [PMID: 33103450 DOI: 10.1152/ajpendo.00391.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Barritt AS 4th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials 2017;61:33-8. [PMID: 28735109 DOI: 10.1016/j.cct.2017.07.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
27 Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, Corey KE, Budoff MJ, Chung RT. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018;259:198-204. [PMID: 29579601 DOI: 10.1016/j.ijcard.2018.01.046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
28 Rivera-Andrade A, Kroker-Lobos MF, Lazo M, Freedman ND, Smith JW, Torres O, McGlynn KA, Groopman JD, Guallar E, Ramirez-Zea M. High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. Nutr Metab Cardiovasc Dis 2019;29:191-200. [PMID: 30573307 DOI: 10.1016/j.numecd.2018.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Zhang M, Hu ML, Huang JJ, Xia SS, Yang Y, Dong K. Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. Chin Med J (Engl) 2019;132:2927-33. [PMID: 31809318 DOI: 10.1097/CM9.0000000000000559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104-1111. [PMID: 27091184 DOI: 10.1007/s00125-016-3944-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
31 Parkin E, O'reilly D, Plumb A, Manoharan P, Rao M, Coe P, Frystyk J, Ammori B, de Liguori Carino N, Deshpande R, Sherlock D, Renehan A. Digital histology quantification of intra-hepatic fat in patients undergoing liver resection. European Journal of Surgical Oncology (EJSO) 2015;41:1020-7. [DOI: 10.1016/j.ejso.2015.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
33 Dasarathy S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology 2014;60:22-5. [PMID: 24644076 DOI: 10.1002/hep.27134] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
34 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 16.6] [Reference Citation Analysis]
35 Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology 2016;63:1170-83. [PMID: 26663021 DOI: 10.1002/hep.28390] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
36 Baciu C, Pasini E, Angeli M, Schwenger K, Afrin J, Humar A, Fischer S, Patel K, Allard J, Bhat M. Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. PLoS One 2017;12:e0189223. [PMID: 29216278 DOI: 10.1371/journal.pone.0189223] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
37 Rivas G, Hummer-Bair B, Bezinover D, Kadry Z, Stine J. Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis. BMJ Open Gastroenterol 2021;8:e000683. [PMID: 34341018 DOI: 10.1136/bmjgast-2021-000683] [Reference Citation Analysis]
38 Chella Krishnan K, Floyd RR, Sabir S, Jayasekera DW, Leon-Mimila PV, Jones AE, Cortez AA, Shravah V, Péterfy M, Stiles L, Canizales-Quinteros S, Divakaruni AS, Huertas-Vazquez A, Lusis AJ. Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner. Cell Mol Gastroenterol Hepatol 2021;11:389-406. [PMID: 32942044 DOI: 10.1016/j.jcmgh.2020.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
39 Haywood CJ, Prendergast LA, Purcell K, Le Fevre L, Lim WK, Galea M, Proietto J. Very Low Calorie Diets for Weight Loss in Obese Older Adults—A Randomized Trial. The Journals of Gerontology: Series A 2018;73:59-65. [DOI: 10.1093/gerona/glx012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
40 Chen VL, Wright AP, Halligan B, Chen Y, Du X, Handelman SK, Long MT, Kiel DP, Speliotes EK. Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Hepatol Commun 2019;3:1073-84. [PMID: 31388628 DOI: 10.1002/hep4.1391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
41 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
42 Item F, Wueest S, Lemos V, Stein S, Lucchini FC, Denzler R, Fisser MC, Challa TD, Pirinen E, Kim Y, Hemmi S, Gulbins E, Gross A, O'Reilly LA, Stoffel M, Auwerx J, Konrad D. Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function. Nat Commun 2017;8:480. [PMID: 28883393 DOI: 10.1038/s41467-017-00566-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
43 Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38-81. [PMID: 30580575 DOI: 10.1161/ATV.0000000000000073] [Cited by in Crossref: 170] [Cited by in F6Publishing: 74] [Article Influence: 85.0] [Reference Citation Analysis]
44 Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19:429-436; discussion 436-437. [PMID: 25537957 DOI: 10.1007/s11605-014-2678-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 10.1] [Reference Citation Analysis]
45 Sapp V, Gaffney L, EauClaire SF, Matthews RP. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition. Hepatology. 2014;60:1581-1592. [PMID: 25043405 DOI: 10.1002/hep.27284] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
46 Harris SE, Poolman TM, Arvaniti A, Cox RD, Gathercole LL, Tomlinson JW. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2020;319:G345-60. [PMID: 32755310 DOI: 10.1152/ajpgi.00055.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P, Fox CS. Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis. Clin Gastroenterol Hepatol 2016;14:1172-1180.e2. [PMID: 27046482 DOI: 10.1016/j.cgh.2016.03.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
48 Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F, Ferrannini E, Loguercio C, Lonardo A, Marra F, Mancini M, Miele L, Nobili V, Baroni GS, Alessandro F, Ballestri S, Rossana Brunetto M, Coco B, Grieco A, Fargion S, Kondili L, Nascimbeni F, Prinster A, Romagnoli D, Taddei S, Vanni E, Vella S. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016;48:333-42. [DOI: 10.1016/j.dld.2015.10.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
49 Al-Dayyat HM, Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr 2018;12:569-75. [PMID: 29571977 DOI: 10.1016/j.dsx.2018.03.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
50 Méndez-sánchez N, Chavez-tapia NC, Almeda-valdes P, Uribe M. The Management of Incidental Fatty Liver Found on Imaging. What Do We Need to do?: . American Journal of Gastroenterology 2018;113:1274-6. [DOI: 10.1038/s41395-018-0047-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8393-8406 [PMID: 25024597 DOI: 10.3748/wjg.v20.i26.8393] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
52 Vincent R, Sanyal A. Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. Curr Pathobiol Rep 2014;2:109-15. [PMID: 25574453 DOI: 10.1007/s40139-014-0049-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
53 Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35:2408-2415. [PMID: 25845417 DOI: 10.1111/liv.12842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
54 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 69] [Article Influence: 11.9] [Reference Citation Analysis]
55 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00567-X. [PMID: 34033923 DOI: 10.1016/j.cgh.2021.05.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology. 2016;64:1969-1977. [PMID: 27301913 DOI: 10.1002/hep.28677] [Cited by in Crossref: 147] [Cited by in F6Publishing: 120] [Article Influence: 29.4] [Reference Citation Analysis]
59 Valdez LA, Morrill KE, Griffith DM, Lindberg NM, Hooker SP, Garcia DO. Mexican Origin Hispanic Men's Perspectives of Physical Activity-Related Health Behaviors. Am J Mens Health 2019;13:1557988319834112. [PMID: 30819068 DOI: 10.1177/1557988319834112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
60 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 228] [Article Influence: 63.0] [Reference Citation Analysis]
61 Stine JG, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol 2017; 9(3): 139-146 [PMID: 28217250 DOI: 10.4254/wjh.v9.i3.139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
62 Hsiao CC, Teng PH, Wu YJ, Shen YW, Mar GY, Wu FZ. Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis. BMC Cardiovasc Disord 2021;21:244. [PMID: 34011282 DOI: 10.1186/s12872-021-02060-z] [Reference Citation Analysis]
63 Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One 2021;16:e0252164. [PMID: 34081733 DOI: 10.1371/journal.pone.0252164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Burch JB, Everson TM, Seth RK, Wirth MD, Chatterjee S. Trihalomethane exposure and biomonitoring for the liver injury indicator, alanine aminotransferase, in the United States population (NHANES 1999-2006). Sci Total Environ 2015;521-522:226-34. [PMID: 25847167 DOI: 10.1016/j.scitotenv.2015.03.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
65 Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J, Anand S. Knowing What's Out There: Awareness of Non-Alcoholic Fatty Liver Disease. Front Med (Lausanne) 2014;1:4. [PMID: 25798442 DOI: 10.3389/fmed.2014.00004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 14] [Article Influence: 7.9] [Reference Citation Analysis]
66 Jullian-Desayes I, Tamisier R, Zarski JP, Aron-Wisnewsky J, Launois-Rollinat SH, Trocme C, Levy P, Joyeux-Faure M, Pepin JL. Impact of effective vs sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials. Respirology. 2016;21:378-385. [PMID: 26567858 DOI: 10.1111/resp.12672] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
67 Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int 2019;13:748-56. [DOI: 10.1007/s12072-019-09987-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
68 Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res. 2014;164:312-322. [PMID: 25028077 DOI: 10.1016/j.trsl.2014.06.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
69 Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, Mccullough A, Alkhouri N. Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Dig Dis Sci 2020;65:978-86. [DOI: 10.1007/s10620-019-05700-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
70 Chella Krishnan K, Mehrabian M, Lusis AJ. Sex differences in metabolism and cardiometabolic disorders. Curr Opin Lipidol 2018;29:404-10. [PMID: 30156571 DOI: 10.1097/MOL.0000000000000536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 20.5] [Reference Citation Analysis]
71 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 205.0] [Reference Citation Analysis]
72 Barritt AS. Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021. Clin Ther 2021;43:436-7. [PMID: 33618858 DOI: 10.1016/j.clinthera.2021.01.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, Chávez-tapia NC, Arrese M, Uribe M, Méndez-sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13:166-78. [DOI: 10.1016/s1665-2681(19)30879-8] [Cited by in Crossref: 82] [Article Influence: 11.7] [Reference Citation Analysis]
74 Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, Osna NA, Kharbanda KK, Seth D, Bautista A. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97:492-510. [PMID: 25217800 DOI: 10.1016/j.yexmp.2014.09.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
75 Shen H, Peng JL, Tayarachakul S, Liangpunsakul S. Association between serum cotinine level and prevalence of non-alcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. J Investig Med 2017;65:43-8. [PMID: 27634642 DOI: 10.1136/jim-2016-000213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
76 Maeso-Díaz R, Boyer-Diaz Z, Lozano JJ, Ortega-Ribera M, Peralta C, Bosch J, Gracia-Sancho J. New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. Cells 2019;8:E1062. [PMID: 31510105 DOI: 10.3390/cells8091062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
77 Biswas M, Kuppili V, Edla DR, Suri HS, Saba L, Marinhoe RT, Sanches JM, Suri JS. Symtosis: A liver ultrasound tissue characterization and risk stratification in optimized deep learning paradigm. Comput Methods Programs Biomed. 2018;155:165-177. [PMID: 29512496 DOI: 10.1016/j.cmpb.2017.12.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 13.3] [Reference Citation Analysis]
78 Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581-587. [PMID: 28195177 DOI: 10.1038/ajg.2017.5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 25.5] [Reference Citation Analysis]
79 Hassani Zadeh S, Salehi-Abargouei A, Mirzaei M, Nadjarzadeh A, Hosseinzadeh M. The association between dietary approaches to stop hypertension diet and mediterranean diet with metabolic syndrome in a large sample of Iranian adults: YaHS and TAMYZ Studies. Food Sci Nutr 2021;9:3932-41. [PMID: 34262749 DOI: 10.1002/fsn3.2387] [Reference Citation Analysis]
80 Chung MY, Mah E, Masterjohn C, Noh SK, Park HJ, Clark RM, Park YK, Lee JY, Bruno RS. Green Tea Lowers Hepatic COX-2 and Prostaglandin E2 in Rats with Dietary Fat-Induced Nonalcoholic Steatohepatitis. J Med Food 2015;18:648-55. [PMID: 25453513 DOI: 10.1089/jmf.2014.0048] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
81 Semmler G, Bachmayer S, Wernly S, Wernly B, Niederseer D, Huber-Schönauer U, Stickel F, Aigner E, Datz C. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. PLoS One 2020;15:e0244514. [PMID: 33382757 DOI: 10.1371/journal.pone.0244514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Chen KW, Meng FC, Shih YL, Su FY, Lin YP, Lin F, Lin JW, Chang WK, Lee CJ, Li YH, Hsieh CB, Lin GM. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018;15:545. [PMID: 29562671 DOI: 10.3390/ijerph15030545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
83 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
84 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(5): 274-283 [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 160] [Cited by in F6Publishing: 148] [Article Influence: 22.9] [Reference Citation Analysis]
85 Likhitsup A, Dundulis J, Ansari S, El-Halawany H, Michelson R, Hutton C, Kennedy K, Helzberg JH, Chhabra R. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019;32:283-286. [PMID: 31040626 DOI: 10.20524/aog.2019.0371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 Yang MH, Sung J, Gwak G. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. Journal of Clinical Lipidology 2016;10:289-98. [DOI: 10.1016/j.jacl.2015.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
87 Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 2019;60:1270-83. [PMID: 31113816 DOI: 10.1194/jlr.M093229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
88 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014.Epub] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
90 Zhai Y, Xiao Q. The Common Mechanisms of Sarcopenia and NAFLD. Biomed Res Int. 2017;2017:6297651. [PMID: 29387723 DOI: 10.1155/2017/6297651] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
91 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
92 Pais P, D'Amato M. In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitis. Drugs R D 2014;14:291-9. [PMID: 25404123 DOI: 10.1007/s40268-014-0068-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
93 Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018;68:251-67. [DOI: 10.1016/j.jhep.2017.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
94 Kim MH, Seong JB, Huh JW, Bae YC, Lee HS, Lee DS. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. Redox Biol 2020;28:101315. [PMID: 31505325 DOI: 10.1016/j.redox.2019.101315] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
95 Hagström H, Höijer J, Ludvigsson JF, Bottai M, Ekbom A, Hultcrantz R, Stephansson O, Stokkeland K. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int 2016;36:268-74. [DOI: 10.1111/liv.12902] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
96 Arab A, Askari G, Golshiri P, Feizi A, Hekmatnia A, Iraj B, Nourian M. The Effect of a Lifestyle Modification Education on Adiposity Measures in Overweight and Obese Nonalcoholic Fatty Liver Disease Patients. Int J Prev Med 2017;8:10. [PMID: 28299034 DOI: 10.4103/2008-7802.200854] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
97 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
98 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
99 Wu S, Tu R, Liu G, Huang L, Guan Y, Zheng E. Focal fatty sparing usually does not arise in preexisting nonalcoholic diffuse homogeneous fatty liver. J Ultrasound Med 2014;33:1447-52. [PMID: 25063410 DOI: 10.7863/ultra.33.8.1447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
100 Saab S, Lalezari D, Pruthi P, Alper T, Tong MJ. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int. 2015;35:164-170. [PMID: 24313970 DOI: 10.1111/liv.12431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
101 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
102 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 12.4] [Reference Citation Analysis]
103 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
104 Olusanya TO, Lesi OA, Adeyomoye AA, Fasanmade OA. Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus. Pan Afr Med J 2016;24:20. [PMID: 27583084 DOI: 10.11604/pamj.2016.24.20.8181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
105 Fingas CD, Best J, Sowa J-P, Canbay A. Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clinical Liver Disease. 2016;8:119-122. [PMID: 31041078 DOI: 10.1002/cld.585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
106 Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018;48:821-828. [PMID: 29679473 DOI: 10.1111/hepr.13179] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
107 Halaoui AF, Ali AH, Habib SG, Kanso M, Daniel F, Mukherji DM, Khalife MJ, Jaafar RF, Faraj W. Gender differences in liver fibrosis among patients younger than 50 years: A retrospective cohort study. Clin Res Hepatol Gastroenterol 2020;44:733-8. [PMID: 32169461 DOI: 10.1016/j.clinre.2020.01.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Chandan S, Mohan BP, Khan SR, Facciorusso A, Ramai D, Kassab LL, Bhogal N, Asokkumar R, Lopez-Nava G, McDonough S, Adler DG. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis. Obes Surg 2021;31:1271-9. [PMID: 33409973 DOI: 10.1007/s11695-020-05084-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Weinberg EM, Trinh HN, Firpi RJ, Bhamidimarri KR, Klein S, Durlam J, Watkins S, Reddy KR, Weiss M, Zink RC, Lok AS. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clin Gastroenterol Hepatol 2021;19:996-1008.e6. [PMID: 32629123 DOI: 10.1016/j.cgh.2020.06.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
110 Zhang TS, Qin HL, Wang T, Li HT, Li H, Xia SH, Xiang XH. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus. 2015;4:776. [PMID: 26697286 DOI: 10.1186/s40064-015-1542-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
111 Tai FW, Syn WK, Alazawi W. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med. 2015; Feb 12. [Epub ahead of print]. [PMID: 25683343 DOI: 10.1111/dme.12725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
112 Gervasoni C, Cattaneo D, Filice C, Galli M; “Gruppo Italiano Studio-NASH in malattie infettive”. Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res 2019;145:104267. [PMID: 31077811 DOI: 10.1016/j.phrs.2019.104267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Herrema H, Zhou Y, Zhang D, Lee J, Salazar Hernandez MA, Shulman GI, Ozcan U. XBP1s Is an Anti-lipogenic Protein. J Biol Chem 2016;291:17394-404. [PMID: 27325692 DOI: 10.1074/jbc.M116.728949] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 8.6] [Reference Citation Analysis]
114 Li W, Zhu X, Song Y, Fan L, Wu L, Kabagambe EK, Hou L, Shrubsole MJ, Liu J, Dai Q. Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr 2018;21:2088-95. [PMID: 29607802 DOI: 10.1017/S1368980018000642] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
115 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 27.0] [Reference Citation Analysis]
116 Peng TC, Kao TW, Wu LW, Chen YJ, Chang YW, Wang CC, Tsao YT, Chen WL. Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study. Medicine (Baltimore) 2015;94:e907. [PMID: 26020401 DOI: 10.1097/MD.0000000000000907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
117 Canbay A, Kachru N, Haas JS, Meise D, Ozbay AB, Sowa JP. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med 2021;9:615. [PMID: 33987313 DOI: 10.21037/atm-20-7179] [Reference Citation Analysis]
118 Mouzaki M, Trout AT. Virtual Reality: New Insights Regarding the Prevalence of Nonalcoholic Fatty Liver Disease in Children and Adolescents with Obesity Using Magnetic Resonance Imaging. The Journal of Pediatrics 2019;207:8-10. [DOI: 10.1016/j.jpeds.2018.12.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017;66:825-33. [PMID: 28470683 DOI: 10.1002/hep.29247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
120 Ma M, Duan R, Zhong H, Liang T, Guo L. The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD. J Immunol Res 2019;2019:3954890. [PMID: 30719457 DOI: 10.1155/2019/3954890] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
121 Shen M, Shi H. Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis. International Journal of Endocrinology 2015;2015:1-12. [DOI: 10.1155/2015/294278] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 13.8] [Reference Citation Analysis]
122 Furlan A, Borhani AA, Heller MT, Yu RK, Tublin ME. Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis. Abdom Radiol (NY) 2016;41:1399-410. [PMID: 26907715 DOI: 10.1007/s00261-016-0685-z] [Reference Citation Analysis]
123 Bruckert E, Ferrières J. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Archives of Cardiovascular Diseases 2014;107:188-200. [DOI: 10.1016/j.acvd.2014.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
124 Meng SX, Liu Q, Tang YJ, Wang WJ, Zheng QS, Tian HJ, Yao DS, Liu L, Peng JH, Zhao Y, Hu YY, Feng Q. A Recipe Composed of Chinese Herbal Active Components Regulates Hepatic Lipid Metabolism of NAFLD In Vivo and In Vitro. Biomed Res Int 2016;2016:1026852. [PMID: 27069915 DOI: 10.1155/2016/1026852] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
125 Flores YN, Velázquez-Cruz R, Ramírez P, Bañuelos M, Zhang ZF, Yee HF Jr, Chang SC, Canizales-Quinteros S, Quiterio M, Cabrera-Alvarez G, Patiño N, Salmerón J. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults. Mol Biol Rep 2016;43:1359-69. [PMID: 27752939 DOI: 10.1007/s11033-016-4058-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
126 Ghoneim S, Dhorepatil A, Shah AR, Ram G, Ahmad S, Kim C, Asaad I. Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. World J Hepatol 2020; 12(7): 378-388 [PMID: 32821336 DOI: 10.4254/wjh.v12.i7.378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Yokoo T, Browning JD. Fat and Iron Quantification in the Liver: Past, Present, and Future. Topics in Magnetic Resonance Imaging 2014;23:73-94. [DOI: 10.1097/rmr.0000000000000016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
128 Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6:3303-25. [PMID: 25195642 DOI: 10.3390/nu6083303] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
129 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
130 Nseir W, Farah R, Mahamid M, Sayed-ahmad H, Mograbi J, Taha M, Artul S. Obesity and recurrent urinary tract infections in premenopausal women: a retrospective study. International Journal of Infectious Diseases 2015;41:32-5. [DOI: 10.1016/j.ijid.2015.10.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
131 Kim SG, Kim BK, Kim K, Fang S. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2016;31:500-4. [PMID: 28029021 DOI: 10.3803/EnM.2016.31.4.500] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
132 Hu W, Zhang W, Chen Y, Rana U, Teng RJ, Duan Y, Liu Z, Zhao B, Foeckler J, Weiler H, Kallinger RE, Thomas MJ, Zhang K, Han J, Miao QR. Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway. Hepatology 2016;64:1559-76. [PMID: 27480224 DOI: 10.1002/hep.28747] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
133 Ahmed HS, Pedersen N, Jayanna MB, Ten Eyck P, Sanchez A, Murali AR. Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. J Gen Intern Med 2020;35:1523-9. [PMID: 32157645 DOI: 10.1007/s11606-020-05725-1] [Reference Citation Analysis]
134 Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, Pastor-Barriuso R, Ahn J, Kim CW, Rampal S. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111:1133-1140. [PMID: 27185080 DOI: 10.1038/ajg.2016.178] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 18.2] [Reference Citation Analysis]
135 Kühn T, Nonnenmacher T, Sookthai D, Schübel R, Quintana Pacheco DA, von Stackelberg O, Graf ME, Johnson T, Schlett CL, Kirsten R, Ulrich CM, Kaaks R, Kauczor HU, Nattenmüller J. Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. BMC Gastroenterol 2018;18:113. [PMID: 30005625 DOI: 10.1186/s12876-018-0840-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
136 Tang K, Zheng X, Lin J, Zheng M, Lin H, Li T, Wang L. Association between non-alcoholic fatty liver disease and myocardial glucose uptake measured by 18F-fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2020;27:1679-88. [PMID: 30238301 DOI: 10.1007/s12350-018-1446-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
137 Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis 2015;2:ofv015. [PMID: 26034765 DOI: 10.1093/ofid/ofv015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
138 Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol 2016; 22(29): 6742-6756 [PMID: 27547017 DOI: 10.3748/wjg.v22.i29.6742] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
139 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 13.0] [Reference Citation Analysis]
140 Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26:1431-1440. [PMID: 26314479 DOI: 10.1007/s00330-015-3949-z] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 19.7] [Reference Citation Analysis]
141 Akie TE, Cooper MP. Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes. J Vis Exp 2015;:e52982. [PMID: 26382148 DOI: 10.3791/52982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
142 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
144 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
145 Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19:1630-1634. [PMID: 28417532 DOI: 10.1111/dom.12973] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 17.5] [Reference Citation Analysis]
146 Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017;96:e8179. [PMID: 28953675 DOI: 10.1097/md.0000000000008179] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 25.3] [Reference Citation Analysis]
147 Wang Y, Liu L, Zhang H, Fan J, Zhang F, Yu M, Shi L, Yang L, Lam SM, Wang H, Chen X, Wang Y, Gao F, Shui G, Xu Z. Mea6 controls VLDL transport through the coordinated regulation of COPII assembly. Cell Res 2016;26:787-804. [PMID: 27311593 DOI: 10.1038/cr.2016.75] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
148 Chen SC, Tsai SP, Jhao JY, Jiang WK, Tsao CK, Chang LY. Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults. Sci Rep 2017;7:4649. [PMID: 28680048 DOI: 10.1038/s41598-017-04631-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 11.5] [Reference Citation Analysis]
149 Loy VM, Joyce C, Bello S, Vonroenn N, Cotler SJ. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32:e13297. [DOI: 10.1111/ctr.13297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrota D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, Miller V; Liver Forum’s Data Standardization Working Group. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. Gastroenterology 2017;153:621-625.e7. [PMID: 28757264 DOI: 10.1053/j.gastro.2017.07.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
151 Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65-76. [PMID: 25376360 DOI: 10.1111/apt.13012] [Cited by in Crossref: 110] [Cited by in F6Publishing: 111] [Article Influence: 15.7] [Reference Citation Analysis]
152 Keyhani-Nejad F, Barbosa Yanez RL, Kemper M, Schueler R, Pivovarova-Ramich O, Rudovich N, Pfeiffer AFH. Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction. Peptides 2020;125:170231. [PMID: 31870938 DOI: 10.1016/j.peptides.2019.170231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
153 Nagpal SJ, Kabbany MN, Mohamad B, Lopez R, Zein NN, Alkhouri N. Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation. Dig Dis Sci 2016;61:2102-7. [PMID: 26993824 DOI: 10.1007/s10620-016-4124-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
154 Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 2020;103:154028. [PMID: 31785257 DOI: 10.1016/j.metabol.2019.154028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
155 Wahlang B, Barney J, Thompson B, Wang C, Hamad OM, Hoffman JB, Petriello MC, Morris AJ, Hennig B. Editor's Highlight: PCB126 Exposure Increases Risk for Peripheral Vascular Diseases in a Liver Injury Mouse Model. Toxicol Sci 2017;160:256-67. [PMID: 28973532 DOI: 10.1093/toxsci/kfx180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
156 Perng W, Francis EC, Smith HA, Carey J, Wang D, Kechris KM, Dabelea D. Sex-Specific Metabolite Biomarkers of NAFLD in Youth: A Prospective Study in the EPOCH Cohort. J Clin Endocrinol Metab 2020;105:dgaa467. [PMID: 32687159 DOI: 10.1210/clinem/dgaa467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Li YH, Yang LH, Sha KH, Liu TG, Zhang LG, Liu XX. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(22): 7008-7013 [PMID: 26078579 DOI: 10.3748/wjg.v21.i22.7008] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
158 Mazi TA, Borkowski K, Newman JW, Fiehn O, Bowlus CL, Sarkar S, Matsukuma K, Ali MR, Kieffer DA, Wan YY, Stanhope KL, Havel PJ, Medici V. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med 2021;172:490-502. [PMID: 34182070 DOI: 10.1016/j.freeradbiomed.2021.06.024] [Reference Citation Analysis]
159 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
160 Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, Ahsan M, Ahmad N. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open 2018;2:39-46. [PMID: 30483562 DOI: 10.1002/jgh3.12044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
161 Cunha GM, Thai TT, Hamilton G, Covarrubias Y, Schlein A, Middleton MS, Wiens CN, McMillan A, Agni R, Funk LM, Campos GM, Horgan S, Jacobson G, Wolfson T, Gamst A, Schwimmer JB, Reeder SB, Sirlin CB. Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity. Abdom Radiol (NY) 2020;45:661-71. [PMID: 31781899 DOI: 10.1007/s00261-019-02350-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
162 Garcia DO, Valdez LA, Aceves B, Bell ML, Humphrey K, Hingle M, McEwen M, Hooker SP. A Gender- and Culturally Sensitive Weight Loss Intervention for Hispanic Men: Results From the Animo Pilot Randomized Controlled Trial. Health Educ Behav 2019;46:763-72. [PMID: 31216875 DOI: 10.1177/1090198119853011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
163 Price JC, Seaberg EC, Latanich R, Budoff MJ, Kingsley LA, Palella FJ Jr, Witt MD, Post WS, Thio CL. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014;109:695-704. [PMID: 24642579 DOI: 10.1038/ajg.2014.32] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
164 Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.Front Oncol. 2019;9:762. [PMID: 31456946 DOI: 10.3389/fonc.2019.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
165 Zhu LZ, Xu S, Qian HL. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World J Gastroenterol 2018; 24(23): 2501-2507 [PMID: 29930471 DOI: 10.3748/wjg.v24.i23.2501] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
166 Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, Razavi H, George J. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020;35:1628-1635. [PMID: 32048317 DOI: 10.1111/jgh.15009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
167 Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. J Clin Gastroenterol 2017;51:160-6. [PMID: 27580477 DOI: 10.1097/MCG.0000000000000666] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
168 Austin P, Gerber L, Paik JM, Price JK, Escheik C, Younossi ZM. Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. J Sports Med Phys Fitness 2019;59. [DOI: 10.23736/s0022-4707.19.09231-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
169 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
170 Song M, Yuan F, Li X, Ma X, Yin X, Rouchka EC, Zhang X, Deng Z, Prough RA, McClain CJ. Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis.Biol Sex Differ. 2021;12:3. [PMID: 33407877 DOI: 10.1186/s13293-020-00346-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Cai X, Fang C, Hayashi S, Hao S, Zhao M, Tsutsui H, Nishiguchi S, Sheng J. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice. J Gastroenterol 2016;51:819-29. [DOI: 10.1007/s00535-015-1154-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
172 Worm N. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. Nutrients 2020;12:E1316. [PMID: 32384593 DOI: 10.3390/nu12051316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
173 Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2015;55:1395-405. [PMID: 26011596 DOI: 10.1002/jcph.550] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
174 McCarty TR, Echouffo-Tcheugui JB, Lange A, Haque L, Njei B. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis. 2018;14:74-80. [PMID: 29055669 DOI: 10.1016/j.soard.2017.09.511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
175 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34:1291-1326. [PMID: 28526997 DOI: 10.1007/s12325-017-0556-1] [Cited by in Crossref: 197] [Cited by in F6Publishing: 188] [Article Influence: 49.3] [Reference Citation Analysis]
176 Shen H, Shahzad G, Jawairia M, Bostick RM, Mustacchia P. Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2014;40:1066-1073. [PMID: 25176122 DOI: 10.1111/apt.12944] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
177 Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol 2013; 5(9): 470-478 [PMID: 24073298 DOI: 10.4254/wjh.v5.i9.470] [Cited by in Crossref: 103] [Cited by in F6Publishing: 43] [Article Influence: 12.9] [Reference Citation Analysis]
178 Lazo M, Mitchell MC. Epidemiology and Risk Factors for Alcoholic Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 1-20. [DOI: 10.1007/978-3-319-20538-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Sodhi K, Puri N, Favero G, Stevens S, Meadows C, Abraham NG, Rezzani R, Ansinelli H, Lebovics E, Shapiro JI. Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet. PLoS One 2015;10:e0128648. [PMID: 26098879 DOI: 10.1371/journal.pone.0128648] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
180 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
181 Gong Z, Tas E, Yakar S, Muzumdar R. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017;455:115-130. [PMID: 28017785 DOI: 10.1016/j.mce.2016.12.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
182 Schübel R, Nonnenmacher T, Sookthai D, Gonzalez Maldonado S, Sowah SA, von Stackelberg O, Schlett CL, Grafetstätter M, Nabers D, Johnson T, Kirsten R, Ulrich CM, Kaaks R, Kauczor HU, Kühn T, Nattenmüller J. Similar Weight Loss Induces Greater Improvements in Insulin Sensitivity and Liver Function among Individuals with NAFLD Compared to Individuals without NAFLD. Nutrients 2019;11:E544. [PMID: 30836637 DOI: 10.3390/nu11030544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Liu X, Henkel AS, LeCuyer BE, Schipma MJ, Anderson KA, Green RM. Hepatocyte X-box binding protein 1 deficiency increases liver injury in mice fed a high-fat/sugar diet. Am J Physiol Gastrointest Liver Physiol. 2015;309:G965-G974. [PMID: 26472223 DOI: 10.1152/ajpgi.00132.2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
184 Neves YCS, Castro-Lima VAC, Solla DJF, Ogata VSM, Pereira FL, Araujo JM, Ho YL, Chammas MC. Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. AJR Am J Roentgenol 2021;216:1392-9. [PMID: 33703928 DOI: 10.2214/AJR.20.23455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Sarkar M, VanWagner LB, Terry JG, Carr JJ, Rinella M, Schreiner PJ, Lewis CE, Terrault N; Coronary Artery Risk Development in Young Adults (CARDIA) Cohort. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol 2019;114:758-63. [PMID: 30730350 DOI: 10.14309/ajg.0000000000000138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
186 Hall Z, Chu Y, Griffin JL. Liquid Extraction Surface Analysis Mass Spectrometry Method for Identifying the Presence and Severity of Nonalcoholic Fatty Liver Disease. Anal Chem 2017;89:5161-70. [DOI: 10.1021/acs.analchem.7b01097] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
187 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70:1457-1469. [PMID: 30924946 DOI: 10.1002/hep.30626] [Cited by in Crossref: 163] [Cited by in F6Publishing: 160] [Article Influence: 81.5] [Reference Citation Analysis]
188 Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100:2231-2238. [PMID: 25885947 DOI: 10.1210/jc.2015-1966] [Cited by in Crossref: 238] [Cited by in F6Publishing: 213] [Article Influence: 39.7] [Reference Citation Analysis]
189 Faasse S, Braun H, Vos M. The role of NAFLD in cardiometabolic disease: an update. F1000Res 2018;7:170. [PMID: 29497497 DOI: 10.12688/f1000research.12028.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
190 Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun 2021;5:938-46. [PMID: 34141981 DOI: 10.1002/hep4.1689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
192 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
193 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 348] [Article Influence: 61.8] [Reference Citation Analysis]
194 El Khoudary SR, Samargandy S, Zeb I, Foster T, de Boer IH, Li D, Budoff MJ. Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort. Nutr Metab Cardiovasc Dis 2020;30:114-22. [PMID: 31761548 DOI: 10.1016/j.numecd.2019.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Jamali R, Pourhassan S, Maghbouli N, Ashraf H, Sohrabpour AA. Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients. Med J Islam Repub Iran. 2020;34:135. [PMID: 33437731 DOI: 10.34171/mjiri.34.135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Eren H, Horsanali MO. The independent association of non-alcoholic fatty liver disease with lower urinary tract symptoms/benign prostatic hyperplasia and erectile function scores. BJU Int 2019;124:329-35. [DOI: 10.1111/bju.14753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
198 Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Orešič M, Hyötyläinen T, Yki-Järvinen H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 2016;64:1167-75. [PMID: 26780287 DOI: 10.1016/j.jhep.2016.01.002] [Cited by in Crossref: 208] [Cited by in F6Publishing: 195] [Article Influence: 41.6] [Reference Citation Analysis]
199 Meroni M, Longo M, Rametta R, Dongiovanni P. Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. Int J Mol Sci. 2018;19:3857. [PMID: 30513996 DOI: 10.3390/ijms19123857] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
200 Danford CJ, Iriana S, Shen C, Curry MP, Lai M. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. Liver Int 2019;39:1165-73. [PMID: 30809932 DOI: 10.1111/liv.14080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
201 Khurana S, Butt W, Khara HS, Johal AS, West SF, Chen ZE, Berger AL, Diehl DL. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. Hepatol Int 2019;13:323-9. [DOI: 10.1007/s12072-019-09945-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
202 Jiang ZG, Tapper EB, Kim M, Connelly MA, Krawczyk SA, Yee EU, Herman MA, Mukamal KJ, Lai M. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2018;52:444-51. [PMID: 28362682 DOI: 10.1097/MCG.0000000000000816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
203 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 594] [Cited by in F6Publishing: 570] [Article Influence: 148.5] [Reference Citation Analysis]
204 Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ 2021;22:505-18. [PMID: 33751289 DOI: 10.1007/s10198-020-01256-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Brady CW. Liver disease in menopause. World J Gastroenterol 2015; 21(25): 7613-7620 [PMID: 26167064 DOI: 10.3748/wjg.v21.i25.7613] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
206 Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS, Pu HQ, Yang AM, He CL, Zhang JP, Ma YB, Zhang YW, Zheng TZ, Bai YN, Cheng N. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis 2019;18:47. [PMID: 30744645 DOI: 10.1186/s12944-019-0984-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
207 Adejumo AC, Samuel GO, Adegbala OM, Adejumo KL, Ojelabi O, Akanbi O, Ogundipe OA, Pani L. Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. Ann Gastroenterol. 2019;32:504-513. [PMID: 31474798 DOI: 10.20524/aog.2019.0402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
208 Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR; Cystic Fibrosis Liver Disease Network (CFLD NET). Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr 2015;167:862-868.e2. [PMID: 26254836 DOI: 10.1016/j.jpeds.2015.06.062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
209 Do A, Lim JK. Epidemiology of nonalcoholic fatty liver disease: A primer. Clin Liver Dis (Hoboken). 2016;7:106-108. [PMID: 31041041 DOI: 10.1002/cld.547] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
210 Sharp KPH, Schultz M, Coppell KJ. Is non-alcoholic fatty liver disease a reflection of what we eat or simply how much we eat? JGH Open 2018;2:59-74. [PMID: 30483565 DOI: 10.1002/jgh3.12040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
211 Umehara T. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. PLoS One 2018;13:e0197900. [PMID: 29897928 DOI: 10.1371/journal.pone.0197900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
212 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study: Hepatology. Hepatology 2019;69:64-75. [DOI: 10.1002/hep.30170] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
213 Gill C, Vatcheva KP, Pan JJ, Smulevitz B, McPherson DD, Fallon M, McCormick JB, Fisher-Hoch SP, Laing ST. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans. Am J Cardiol 2017;119:1717-22. [PMID: 28395890 DOI: 10.1016/j.amjcard.2017.03.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
214 Murali AR, Gupta A, Brown K. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. Hepatol Res 2018;48:E30-41. [PMID: 28593739 DOI: 10.1111/hepr.12921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
215 Tipirneni-Sajja A, Krafft AJ, Loeffler RB, Song R, Bahrami A, Hankins JS, Hillenbrand CM. Autoregressive moving average modeling for hepatic iron quantification in the presence of fat. J Magn Reson Imaging 2019;50:1620-32. [PMID: 30761652 DOI: 10.1002/jmri.26682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
216 Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015;14:119-127. [PMID: 26114083 DOI: 10.1007/s11901-015-0260-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
217 Bonci E, Chiesa C, Versacci P, Anania C, Silvestri L, Pacifico L. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:213737. [PMID: 26273598 DOI: 10.1155/2015/213737] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
218 Simon TG, Kartoun U, Zheng H, Chan AT, Chung RT, Shaw S, Corey KE. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun 2017;1:429-38. [PMID: 29085919 DOI: 10.1002/hep4.1051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
219 Valery PC, Powell E, Moses N, Volk ML, McPhail SM, Clark PJ, Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open. 2015;5:e007451. [PMID: 25854973 DOI: 10.1136/bmjopen-2014-007451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
220 Hejlova I, Honsova E, Sticova E, Lanska V, Hucl T, Spicak J, Jirsa M, Trunecka P. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22:644-655. [PMID: 26707008 DOI: 10.1002/lt.24393] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
221 Machado MV, Diehl AM. Liver renewal: detecting misrepair and optimizing regeneration. Mayo Clin Proc 2014;89:120-30. [PMID: 24388030 DOI: 10.1016/j.mayocp.2013.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
222 Lam B, Kurzke K, Younossi Z. The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Curr Hepatology Rep 2018;17:345-9. [DOI: 10.1007/s11901-018-0423-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Strakovsky RS, Wang H, Engeseth NJ, Flaws JA, Helferich WG, Pan YX, Lezmi S. Developmental bisphenol A (BPA) exposure leads to sex-specific modification of hepatic gene expression and epigenome at birth that may exacerbate high-fat diet-induced hepatic steatosis. Toxicol Appl Pharmacol. 2015;284:101-112. [PMID: 25748669 DOI: 10.1016/j.taap.2015.02.021] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 14.3] [Reference Citation Analysis]
224 Wu L, Zhu X, Fan L, Kabagambe EK, Song Y, Tao M, Zhong X, Hou L, Shrubsole MJ, Liu J, Dai Q. Magnesium intake and mortality due to liver diseases: Results from the Third National Health and Nutrition Examination Survey Cohort. Sci Rep 2017;7:17913. [PMID: 29263344 DOI: 10.1038/s41598-017-18076-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
225 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
226 Makris KC, Andrianou XD, Charisiadis P, Burch JB, Seth RK, Ioannou A, Picolos M, Christophi CA, Chatterjee S. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. Environment International 2016;92-93:486-93. [DOI: 10.1016/j.envint.2016.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
227 Wang A, Lazo M, Carter HB, Groopman JD, Nelson WG, Platz EA. Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010. Cancer Epidemiol Biomarkers Prev. 2019;28:1331-1338. [PMID: 31160348 DOI: 10.1158/1055-9965.epi-19-0145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
228 Sivakumar J, Chong L, Ward S, Sutherland TR, Read M, Hii MW. Body Composition Changes Following a Very-Low-Calorie Pre-Operative Diet in Patients Undergoing Bariatric Surgery. Obes Surg 2020;30:119-26. [PMID: 31529393 DOI: 10.1007/s11695-019-04174-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
229 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Ćulafić M, Vezmar-Kovačević S, Dopsaj V, Oluić B, Bidžić N, Miljković B, Ćulafić Đ. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. J Med Biochem 2020;39:290-8. [PMID: 33269017 DOI: 10.2478/jomb-2019-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 C. Gordon S, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol 2020;115:562-74. [DOI: 10.14309/ajg.0000000000000484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
232 Jeon BH, Lee Y, Yun MR, Kim SH, Lee BW, Kang ES, Lee HC, Cha B. Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. Metabolism 2015;64:1444-53. [DOI: 10.1016/j.metabol.2015.07.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
233 Foster MT, Gentile CL, Cox-york K, Wei Y, Wang D, Estrada AL, Reese L, Miller T, Pagliassotti MJ, Weir TL. Fuzhuan tea consumption imparts hepatoprotective effects and alters intestinal microbiota in high saturated fat diet-fed rats. Mol Nutr Food Res 2016;60:1213-20. [DOI: 10.1002/mnfr.201500654] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
234 Dhaliwal J, Chavhan GB, Lurz E, Shalabi A, Yuen N, Williams B, Martincevic I, Amirabadi A, Wales PW, Lee W, Ling SC, Mouzaki M. Hepatic steatosis is highly prevalent across the paediatric age spectrum, including in pre-school age children. Aliment Pharmacol Ther 2018;48:556-63. [PMID: 29998462 DOI: 10.1111/apt.14900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Federico A, Dallio M, Caprio GG, Gravina AG, Picascia D, Masarone M, Persico M, Loguercio C. Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. Nutrients 2017;9:E1074. [PMID: 28956816 DOI: 10.3390/nu9101074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
236 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
237 Zhu H, Wang Z, Wu Y, Jiang H, Zhou F, Xie X, Wang R, Hua C. Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease. Int J Biol Macromol 2019;128:363-75. [PMID: 30690116 DOI: 10.1016/j.ijbiomac.2019.01.141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
238 Kwon EY, Kim YR, Kang DM, Yoon KH, Lee YH. Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. Clin Imaging 2021;76:53-9. [PMID: 33549920 DOI: 10.1016/j.clinimag.2021.01.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Jung JY, Shim JJ, Park SK, Ryoo JH, Choi JM, Oh IH, Jung KW, Cho H, Ki M, Won YJ, Oh CM. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int 2019;13:222-33. [PMID: 30182166 DOI: 10.1007/s12072-018-9892-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
240 Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014; 20(24): 7718-7729 [PMID: 24976709 DOI: 10.3748/wjg.v20.i24.7718] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
241 Kallwitz E, Tayo BO, Kuniholm MH, Daviglus M, Zeng D, Isasi CR, Cotler SJ. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. Liver Int 2020;40:889-93. [PMID: 31965669 DOI: 10.1111/liv.14387] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
242 Flores YN, Auslander A, Crespi CM, Rodriguez M, Zhang ZF, Durazo F, Salmerón J. Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers. J Dig Dis 2016;17:304-12. [PMID: 26991251 DOI: 10.1111/1751-2980.12341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
243 Remigio-Baker RA, Allison MA, Forbang NI, Loomba R, Anderson CAM, Budoff M, Schwimmer JB, Blumenthal RS, Ouyang P, Criqui MH. Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2017;258:89-96. [PMID: 28235711 DOI: 10.1016/j.atherosclerosis.2016.11.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
244 Han H, Qiu F, Zhao H, Tang H, Li X, Shi D. Dietary Flaxseed Oil Prevents Western-Type Diet-Induced Nonalcoholic Fatty Liver Disease in Apolipoprotein-E Knockout Mice. Oxid Med Cell Longev 2017;2017:3256241. [PMID: 29081885 DOI: 10.1155/2017/3256241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
245 Yu E, Hsu HY, Huang CY, Hwang LC. Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease. Open Med (Wars) 2018;13:208-13. [PMID: 29845121 DOI: 10.1515/med-2018-0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
246 Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2019;4:217-26. [PMID: 30573390 DOI: 10.1016/S2468-1253(18)30339-X] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
247 Shi Y, Huang B, Deng R, Ma Y. The Association of obesity with vascular complications after liver transplantation. BMC Gastroenterol 2019;19:39. [PMID: 30845923 DOI: 10.1186/s12876-019-0954-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
248 Li M, Ye T, Wang XX, Li X, Qiang O, Yu T, Tang CW, Liu R. Effect of Octreotide on Hepatic Steatosis in Diet-Induced Obesity in Rats. PLoS One. 2016;11:e0152085. [PMID: 27002331 DOI: 10.1371/journal.pone.0152085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
249 Chung M, Shin EJ, Choi H, Kim SH, Sung MJ, Park JH, Hwang J. Schisandra chinensis berry extract protects against steatosis by inhibiting histone acetylation in oleic acid–treated HepG2 cells and in the livers of diet-induced obese mice. Nutrition Research 2017;46:1-10. [DOI: 10.1016/j.nutres.2017.07.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
250 Sharma M, Kulkarni A, Kumar P, Nori VB, Jagtap N, Gupta R, Reddy DN, Rao PN. Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects. Sci Rep 2020;10:15232. [PMID: 32943747 DOI: 10.1038/s41598-020-72306-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54:1472-80. [PMID: 34694013 DOI: 10.1111/apt.16674] [Reference Citation Analysis]
252 Samji NS, Snell PD, Singal AK, Satapathy SK. Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2020;16:66-72. [PMID: 32922753 DOI: 10.1002/cld.948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
253 Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41:1227-42. [PMID: 33590598 DOI: 10.1111/liv.14825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
254 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
255 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Ugamura A, Chu PS, Nakamoto N, Taniki N, Ojiro K, Hibi T, Shinoda M, Obara H, Masugi Y, Yamaguchi A, Shiba S, Morikawa R, Usui S, Ebinuma H, Kitagawa Y, Saito H, Kanai T. Liver Fibrosis Markers Improve Prediction of Outcome in Non-Acetaminophen-Associated Acute Liver Failure. Hepatol Commun 2018;2:1331-43. [PMID: 30411080 DOI: 10.1002/hep4.1233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
257 Okafor PN, Chiejina M, de Pretis N, Talwalkar JA. Secondary analysis of large databases for hepatology research. Journal of Hepatology 2016;64:946-56. [DOI: 10.1016/j.jhep.2015.12.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
258 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-665. [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183] [Cited by in Crossref: 559] [Cited by in F6Publishing: 528] [Article Influence: 69.9] [Reference Citation Analysis]
259 Unalp-arida A, Ruhl CE. Liver fat scores predict liver disease mortality in the United States population. Aliment Pharmacol Ther 2018;48:1003-16. [DOI: 10.1111/apt.14967] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
260 Abdel-Hamid NM, Abass SA, Mohamed AA, Muneam Hamid D. Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors. Biomed Pharmacother. 2018;107:1246-1258. [PMID: 30257339 DOI: 10.1016/j.biopha.2018.08.104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
261 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
262 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
263 Chang HT, Pan HJ, Lee CH. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. Clin Breast Cancer 2018;18:e677-85. [PMID: 29287963 DOI: 10.1016/j.clbc.2017.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
264 Garcia AE, Kasim N, Tamboli RA, Gonzalez RS, Antoun J, Eckert EA, Marks-Shulman PA, Dunn J, Wattacheril J, Wallen T, Abumrad NN, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One 2015;10:e0142676. [PMID: 26599819 DOI: 10.1371/journal.pone.0142676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
265 Hosick PA, Weeks MF, Hankins MW, Moore KH, Stec DE. Sex-Dependent Effects of HO-1 Deletion from Adipocytes in Mice. Int J Mol Sci 2017;18:E611. [PMID: 28287466 DOI: 10.3390/ijms18030611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
266 Zhao L, Zhang C, Luo X, Wang P, Zhou W, Zhong S, Xie Y, Jiang Y, Yang P, Tang R, Pan Q, Hall AR, Luong TV, Fan J, Varghese Z, Moorhead JF, Pinzani M, Chen Y, Ruan XZ. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J Hepatol 2018;69:705-17. [PMID: 29705240 DOI: 10.1016/j.jhep.2018.04.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
267 Chen VL, Hawa F, Berinstein JA, Reddy CA, Kassab I, Platt KD, Hsu CY, Steiner CA, Louissaint J, Gunaratnam NT, Sharma P. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. Dig Dis Sci. 2020;. [PMID: 32980956 DOI: 10.1007/s10620-020-06618-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
268 Yang Y, Kim B, Park YK, Koo SI, Lee JY. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochim Biophys Acta. 2015;1850:178-185. [PMID: 25450180 DOI: 10.1016/j.bbagen.2014.10.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
269 Wu LM, He H, Chen G, Kuang Y, Lin BY, Chen XH, Zheng SS. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. Hepatobiliary Pancreat Dis Int 2020;19:252-7. [PMID: 32205038 DOI: 10.1016/j.hbpd.2020.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
270 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
271 Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, Chen CS, Wang WH, Mar GY, Yu HC. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. Clin Transl Gastroenterol. 2019;10:1-8. [PMID: 31082856 DOI: 10.14309/ctg.0000000000000042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
272 Russo MW, Koteish AA, Fuchs M, Reddy KG, Fix OK. Workforce in hepatology: Update and a critical need for more information. Hepatology 2017;65:336-40. [PMID: 27628621 DOI: 10.1002/hep.28810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
273 Guo Q, Shi Q, Li H, Liu J, Wu S, Sun H, Zhou B. Glycolipid Metabolism Disorder in the Liver of Obese Mice Is Improved by TUDCA via the Restoration of Defective Hepatic Autophagy. Int J Endocrinol 2015;2015:687938. [PMID: 26681941 DOI: 10.1155/2015/687938] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
274 Wojcicki JM, Rehkopf D, Epel E, Rosenthal P. Shorter Leukocyte Telomere Length in Relation to Presumed Nonalcoholic Fatty Liver Disease in Mexican-American Men in NHANES 1999-2002. Int J Hepatol 2017;2017:8435178. [PMID: 28740738 DOI: 10.1155/2017/8435178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
275 Galloway CA, Lee H, Brookes PS, Yoon Y. Decreasing mitochondrial fission alleviates hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2014;307:G632-G641. [PMID: 25080922 DOI: 10.1152/ajpgi.00182.2014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
276 Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
277 Likhitsup A, Dundulis J, Ansari S, Patibandla S, Hutton C, Kennedy K, Helzberg JH, Chhabra R. High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. Ann Gastroenterol. 2019;32:463-468. [PMID: 31474792 DOI: 10.20524/aog.2019.0405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
278 Motamed N, Rabiee B, Poustchi H, Dehestani B, Hemasi GR, Khonsari MR, Maadi M, Saeedian FS, Zamani F. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol. 2017;41:31-38. [PMID: 27597641 DOI: 10.1016/j.clinre.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
279 Florio AA, Graubard BI, Yang B, Thistle JE, Bradley MC, McGlynn KA, Petrick JL. Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink. Eur J Epidemiol 2019;34:871-8. [PMID: 31165323 DOI: 10.1007/s10654-019-00526-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
280 Zhai Y, Xiao Q, Miao J. The Relationship between NAFLD and Sarcopenia in Elderly Patients. Can J Gastroenterol Hepatol 2018;2018:5016091. [PMID: 29785395 DOI: 10.1155/2018/5016091] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
281 Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol 2014; 20(23): 7366-7380 [PMID: 24966607 DOI: 10.3748/wjg.v20.i23.7366] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
282 Jäger S, Jacobs S, Kröger J, Stefan N, Fritsche A, Weikert C, Boeing H, Schulze MB. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One. 2015;10:e0124749. [PMID: 25902304 DOI: 10.1371/journal.pone.0124749] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
283 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 16.8] [Reference Citation Analysis]
284 Naganawa S, Enooku K, Tateishi R, Akai H, Yasaka K, Shibahara J, Ushiku T, Abe O, Ohtomo K, Kiryu S. Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. Eur Radiol. 2018;28:3050-3058. [PMID: 29404772 DOI: 10.1007/s00330-017-5270-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
285 Ehrlich A, Tsytkin-Kirschenzweig S, Ioannidis K, Ayyash M, Riu A, Note R, Ouedraogo G, Vanfleteren J, Cohen M, Nahmias Y. Microphysiological flux balance platform unravels the dynamics of drug induced steatosis. Lab Chip 2018;18:2510-22. [PMID: 29992215 DOI: 10.1039/c8lc00357b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
286 Flamm SL. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Am J Med Sci. 2018;356:296-303. [PMID: 30286824 DOI: 10.1016/j.amjms.2018.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
287 Attenberger UI, Morelli J, Budjan J, Henzler T, Sourbron S, Bock M, Riffel P, Hernando D, Ong MM, Schoenberg SO. Fifty Years of Technological Innovation: Potential and Limitations of Current Technologies in Abdominal Magnetic Resonance Imaging and Computed Tomography. Invest Radiol. 2015;50:584-593. [PMID: 26039773 DOI: 10.1097/rli.0000000000000173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 3.4] [Reference Citation Analysis]
288 Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Res 2017;6:1630. [PMID: 29093809 DOI: 10.12688/f1000research.12417.2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
289 Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol. 2014;29:2006-2013. [PMID: 25039333 DOI: 10.1111/jgh.12665] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
290 Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology 2017;65:853-63. [PMID: 27981599 DOI: 10.1002/hep.28968] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
291 Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016;119:143-56. [PMID: 27543499 DOI: 10.1093/bmb/ldw031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
292 Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006. [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004] [Cited by in Crossref: 246] [Cited by in F6Publishing: 224] [Article Influence: 41.0] [Reference Citation Analysis]
293 Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499. [PMID: 28346543 DOI: 10.1371/journal.pone.0173499] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 29.0] [Reference Citation Analysis]
294 Meyer ML, Sotres-Alvarez D, Steiner AZ, Cousins L, Talavera GA, Cai J, Daviglus ML, Loehr LR. Polycystic Ovary Syndrome Signs and Metabolic Syndrome in Premenopausal Hispanic/Latina Women: the HCHS/SOL Study. J Clin Endocrinol Metab 2020;105:dgaa012. [PMID: 31917455 DOI: 10.1210/clinem/dgaa012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 172] [Article Influence: 37.2] [Reference Citation Analysis]
296 Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18-24. [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 35.0] [Reference Citation Analysis]
297 Raffaele M, Licari M, Amin S, Alex R, Shen HH, Singh SP, Vanella L, Rezzani R, Bonomini F, Peterson SJ, Stec DE, Abraham NG. Cold Press Pomegranate Seed Oil Attenuates Dietary-Obesity Induced Hepatic Steatosis and Fibrosis through Antioxidant and Mitochondrial Pathways in Obese Mice. Int J Mol Sci 2020;21:E5469. [PMID: 32751794 DOI: 10.3390/ijms21155469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
298 Young KA, Palmer ND, Fingerlin TE, Langefeld CD, Norris JM, Wang N, Xiang AH, Guo X, Williams AH, Chen YI, Taylor KD, Rotter JI, Raffel LJ, Goodarzi MO, Watanabe RM, Wagenknecht LE. Genome-Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: The GUARDIAN Consortium. Obesity (Silver Spring) 2019;27:1331-7. [PMID: 31219225 DOI: 10.1002/oby.22527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
299 Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2021. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Reference Citation Analysis]
300 Goyal NP, Schwimmer JB. The Genetics of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2018;22:59-71. [PMID: 29128061 DOI: 10.1016/j.cld.2017.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
301 Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14:168-178. [PMID: 31195434 DOI: 10.5009/gnl19069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
302 Núñez KG, Frank A, Gonzalez-Rosario J, Galliano G, Bridle K, Crawford D, Seal J, Abbruscato F, Vashistha H, Thevenot PT, Cohen AJ. Interleukin-33 / Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury. PLoS One 2019;14:e0216242. [PMID: 31034519 DOI: 10.1371/journal.pone.0216242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
303 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
304 Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66:84-95. [PMID: 28195363 DOI: 10.1002/hep.29113] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 18.8] [Reference Citation Analysis]
305 Aneni EC, Bittencourt MS, Teng C, Cainzos-Achirica M, Osondu CU, Soliman A, Al-Mallah M, Buddoff M, Parise ER, Santos RD, Nasir K. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. Am J Prev Cardiol 2020;4:100097. [PMID: 34327473 DOI: 10.1016/j.ajpc.2020.100097] [Reference Citation Analysis]
306 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
307 Tajima R, Imamura F, Kimura T, Kobayashi S, Masuda K, Iida K. Association of alcohol consumption with prevalence of fatty liver after adjustment for dietary patterns: Cross-sectional analysis of Japanese middle-aged adults. Clin Nutr 2020;39:1580-6. [PMID: 31427182 DOI: 10.1016/j.clnu.2019.07.001] [Reference Citation Analysis]
308 Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost. 2016;14:1337-1349. [PMID: 27060337 DOI: 10.1111/jth.13327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
309 Wildman-Tobriner B, Middleton MM, Moylan CA, Rossi S, Flores O, Chang ZA, Abdelmalek MF, Sirlin CB, Bashir MR. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. Gastroenterology 2018;155:1428-1435.e2. [PMID: 30031769 DOI: 10.1053/j.gastro.2018.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
310 Nyberg LM, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. Hepatol Commun 2021;5:83-96. [PMID: 33437903 DOI: 10.1002/hep4.1625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
311 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
312 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 35.5] [Reference Citation Analysis]
313 Elzouki AN. Probiotics and Liver Disease: Where Are We Now and Where Are We Going? J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & amp; New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S188-S190. [PMID: 27741172 DOI: 10.1097/mcg.0000000000000712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
314 VoPham T. Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. Curr Epidemiol Rep 2019;6:50-66. [PMID: 31080703 DOI: 10.1007/s40471-019-0183-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
315 Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis 2018;17:196. [PMID: 30131058 DOI: 10.1186/s12944-018-0848-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
316 Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet Med 2017;34:505-13. [PMID: 27334577 DOI: 10.1111/dme.13174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
317 Buday B, Pach PF, Literati-Nagy B, Vitai M, Kovacs G, Vecsei Z, Koranyi L, Lengyel C. Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: Why alanine aminotransferase only predicts cardiovascular risk in men? Cardiovasc Diabetol 2015;14:55. [PMID: 25986611 DOI: 10.1186/s12933-015-0222-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
318 Mantovani A, Targher G, Zoppini G. Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. Clinics in Geriatric Medicine 2020;36:527-47. [DOI: 10.1016/j.cger.2020.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
319 Motamed N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, Perumal D, Ashrafi GH, Faraji AH, Maadi M, Ajdarkosh H, Safarnezhad Tameshkel F, Moradi-Lakeh M, Miri SM, Arsang-Jang S, Zamani F. The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study. Clin Res Hepatol Gastroenterol 2021;45:101567. [PMID: 33711631 DOI: 10.1016/j.clinre.2020.10.011] [Reference Citation Analysis]
320 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Dietary Reference Values for choline. EFS2 2016;14. [DOI: 10.2903/j.efsa.2016.4484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 6.8] [Reference Citation Analysis]
321 Akinkugbe AA, Slade GD, Barritt AS, Cole SR, Offenbacher S, Petersmann A, Kocher T, Lerch MM, Mayerle J, Völzke H, Heiss G, Holtfreter B. Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania. J Clin Periodontol 2017;44:1077-87. [PMID: 28804947 DOI: 10.1111/jcpe.12800] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
322 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
323 Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-2094 [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 19.0] [Reference Citation Analysis]
324 Kulathunga K, Wakimoto A, Hiraishi Y, Yadav MK, Gentleman K, Warabi E, Sakasai T, Miwa Y, Mizuno S, Takahashi S, Hamada M. Albino mice with the point mutation at the tyrosinase locus show high cholesterol diet-induced NASH susceptibility. Sci Rep 2021;11:21827. [PMID: 34750345 DOI: 10.1038/s41598-021-00501-5] [Reference Citation Analysis]
325 Mehta R, Birerdinc A, Younossi ZM. Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin Liver Dis 2014;18:249-67. [PMID: 24274878 DOI: 10.1016/j.cld.2013.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
326 DiNicolantonio JJ, Subramonian AM, O'Keefe JH. Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis. Open Heart 2017;4:e000631. [PMID: 29118995 DOI: 10.1136/openhrt-2017-000631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
327 Zhou X, Li Y, Zhang X, Guan YY, Puentes Y, Zhang F, Speliotes EK, Ji L. Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. Diabetes Metab Res Rev 2019;35:e3156. [PMID: 30892820 DOI: 10.1002/dmrr.3156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
328 Gellert-Kristensen H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant. Hepatology. 2020;71:56-66. [PMID: 31155741 DOI: 10.1002/hep.30799] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
329 Kim EJ, Kim HJ. Nonalcoholic fatty liver disease in obese and nonobese pediatric patients. Korean J Pediatr 2019;62:30-5. [PMID: 30304905 DOI: 10.3345/kjp.2018.06786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
330 Folsom AR, Lutsey PL, Roetker NS, Rosamond WD, Lazo M, Heckbert SR, Basu S, Cushman M, Selvin E. Elevated hepatic enzymes and incidence of venous thromboembolism: a prospective study. Ann Epidemiol 2014;24:817-821.e2. [PMID: 25277506 DOI: 10.1016/j.annepidem.2014.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
331 Ajmera VH, Terrault NA, VanWagner LB, Sarkar M, Lewis CE, Carr JJ, Gunderson EP. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol 2019;70:126-32. [PMID: 30392752 DOI: 10.1016/j.jhep.2018.09.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
332 Morrill KE, Bland VL, Klimentidis YC, Hingle MD, Thomson CA, Garcia DO. Assessing Interactions between PNPLA3 and Dietary Intake on Liver Steatosis in Mexican-Origin Adults. Int J Environ Res Public Health 2021;18:7055. [PMID: 34280991 DOI: 10.3390/ijerph18137055] [Reference Citation Analysis]
333 Olefson S, Jackson M, Grand DJ, Charpentier KP, Makwana N, Promrat K. Identification of Nonalcoholic Fatty Liver Disease following Pancreatic Surgery in a Western Cohort Using a Novel Radiographic Technique. J Clin Transl Hepatol 2015;3:246-53. [PMID: 26807379 DOI: 10.14218/JCTH.2015.00029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
334 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Mindikoglu AL, Opekun AR, Gagan SK, Devaraj S. Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2017;2017:3932491. [PMID: 29348746 DOI: 10.1155/2017/3932491] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
336 Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179:16-29. [PMID: 29235656 DOI: 10.1111/bjd.16239] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
337 Chen HM, Lee LC, Hu KY, Tsai WJ, Huang C, Tsay HJ, Liu HK. The application of post-translational modification oriented serum proteomics to assess experimental diabetes with complications. PLoS One 2018;13:e0206509. [PMID: 30395577 DOI: 10.1371/journal.pone.0206509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
338 Vos MB, Dimick-santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE, Adda N, Baldyga W, Banerjee R, Behling C, Boulos S, Burgess G, Calboli D, Charles E, Christian R, Cohen-bacrie C, Cosma-roman D, Danzer C, Delaet I, Delegge M, Dimick-santos L, Diprospero N, Donohue K, Fischer L, Fitzpatrick E, Fried M, Hagerty D, Hale P, Hildick K, Hum D, Jamil K, Jiang L, Karpen S, Kelly M, Kleiner DE, Kohli R, Kordy K, Krieger N, Lavine J, Lee L, Lefebvre E, Lopez P, Lyons E, Malahias L, Megnien S, Mehta R, Mesenbrink P, Miller V, Minnick P, Murray C, Nghiem T, Nicholson N, Noviello S, Omokaro SO, Pang W, Percival L, Peres D, Powell M, Roman D, Root M, Sampson C, Sanyal A, Schabel E, Schwarz K, Schwimmer JB, Seyedkazemi S, Shapiro D, Shringarpure R, Silberg D, Smith E, Socha P, Squires R, Szitanyi P, Taminiau J, Torstenson R, Treem W, Vig P, Vos M, Yamashita M, Zemel M. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1448-1456.e1. [DOI: 10.1053/j.gastro.2019.08.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
339 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
340 Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, Müller M, Beekman M, Steegenga WT. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep 2016;6:30484. [PMID: 27470139 DOI: 10.1038/srep30484] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
341 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
342 Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 2015;151:99-106. [PMID: 25805597 DOI: 10.1016/j.pharmthera.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
343 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 362] [Article Influence: 127.0] [Reference Citation Analysis]
344 Kim TJ, Sinn DH, Min YW, Son HJ, Kim JJ, Chang Y, Baek SY, Ahn SH, Lee H, Ryu S. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. J Gastroenterol 2017;52:1201-10. [PMID: 28382402 DOI: 10.1007/s00535-017-1337-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
345 Yki-järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The Lancet Diabetes & Endocrinology 2014;2:901-10. [DOI: 10.1016/s2213-8587(14)70032-4] [Cited by in Crossref: 528] [Cited by in F6Publishing: 279] [Article Influence: 75.4] [Reference Citation Analysis]
346 Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26:444-453. [PMID: 31968197 DOI: 10.4158/ep-2019-0342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
347 Bhatt SP, Misra A, Pandey RM. rs7903146 (C/T) polymorphism of Transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians. Diabetes Metab Syndr 2020;14:175-80. [PMID: 32142998 DOI: 10.1016/j.dsx.2020.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
348 Gan D, Wang L, Jia M, Ru Y, Ma Y, Zheng W, Zhao X, Yang F, Wang T, Mu Y, Zhu S. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr 2020;39:1124-30. [PMID: 31053512 DOI: 10.1016/j.clnu.2019.04.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
349 Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJG, Freeman SC, Cooper NJ, Sutton AJ, Fritche D, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;6:CD013156. [PMID: 34114650 DOI: 10.1002/14651858.CD013156.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
350 Riazi K, Raman M, Taylor L, Swain MG, Shaheen AA. Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer? Nutrients 2019;11:E2878. [PMID: 31779112 DOI: 10.3390/nu11122878] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
351 Nguyen AL, Park H, Nguyen P, Sheen E, Kim YA, Nguyen MH. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. Dig Dis Sci 2019;64:698-707. [DOI: 10.1007/s10620-018-5326-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
352 Campbell P, Symonds A, Barritt AS 4th. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clin Ther 2021;43:500-17. [PMID: 33583577 DOI: 10.1016/j.clinthera.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
353 Go YM, Sutliff RL, Chandler JD, Khalidur R, Kang BY, Anania FA, Orr M, Hao L, Fowler BA, Jones DP. Low-Dose Cadmium Causes Metabolic and Genetic Dysregulation Associated With Fatty Liver Disease in Mice. Toxicol Sci 2015;147:524-34. [PMID: 26187450 DOI: 10.1093/toxsci/kfv149] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
354 Borji M, Nourbakhsh M, Shafiee SM, Owji AA, Abdolvahabi Z, Hesari Z, Ilbeigi D, Seiri P, Yousefi Z. Down-Regulation of SIRT1 Expression by mir-23b Contributes to Lipid Accumulation in HepG2 Cells. Biochem Genet 2019;57:507-21. [PMID: 30697640 DOI: 10.1007/s10528-019-09905-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
355 Pillon Barcelos R, Freire Royes LF, Gonzalez-Gallego J, Bresciani G. Oxidative stress and inflammation: liver responses and adaptations to acute and regular exercise. Free Radic Res 2017;51:222-36. [PMID: 28166653 DOI: 10.1080/10715762.2017.1291942] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
356 Pan H, Chang H, Lee C. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. Journal of the Formosan Medical Association 2016;115:411-7. [DOI: 10.1016/j.jfma.2015.05.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
357 Moore Heslin A, O'Donnell A, Buffini M, Nugent AP, Walton J, Flynn A, McNulty BA. Risk of Iron Overload in Obesity and Implications in Metabolic Health. Nutrients 2021;13:1539. [PMID: 34063273 DOI: 10.3390/nu13051539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Dai W, Wang K, Zheng X, Chen X, Zhang W, Zhang Y, Hou J, Liu L. High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs. Nutr Metab (Lond) 2015;12:42. [PMID: 26583037 DOI: 10.1186/s12986-015-0036-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
359 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
360 Sun J, Tang Y, Yu X, Xu Y, Liu P, Xiao L, Liu L, Deng Q, Yao P. Flaxseed lignans alleviate high fat diet-induced hepatic steatosis and insulin resistance in mice: Potential involvement of AMP-activated protein kinase. Journal of Functional Foods 2016;24:482-91. [DOI: 10.1016/j.jff.2016.04.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
361 Arslan U, Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases 2020; 8(20): 4688-4699 [PMID: 33195636 DOI: 10.12998/wjcc.v8.i20.4688] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
362 Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83-95. [PMID: 26369383 DOI: 10.1111/apt.13405] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 18.2] [Reference Citation Analysis]
363 Kucsera D, Tóth VE, Gergő D, Vörös I, Onódi Z, Görbe A, Ferdinandy P, Varga ZV. Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. Front Physiol 2021;12:609465. [PMID: 33692700 DOI: 10.3389/fphys.2021.609465] [Reference Citation Analysis]
364 Xu G, Ye J, Liu X, Zhang N, Zhao Y, Fan J, Liu X, Wu J. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. Lab Invest 2017;97:1201-17. [DOI: 10.1038/labinvest.2017.84] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
365 Lazo M, Bilal U, Mitchell MC, Potter J, Hernaez R, Clark JM. Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clin Gastroenterol Hepatol 2021;19:2606-2614.e4. [PMID: 32882427 DOI: 10.1016/j.cgh.2020.08.054] [Reference Citation Analysis]
366 de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition 2018;37:37-55. [DOI: 10.1016/j.clnu.2017.01.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
367 Said A. Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. World J Gastroenterol 2013; 19(48): 9146-9155 [PMID: 24409043 DOI: 10.3748/wjg.v19.i48.9146] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
368 Kim MK, Chae YN, Ahn GJ, Shin CY, Choi SH, Yang EK, Sohn YS, Son MH. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models. Arch Pharm Res 2017;40:268-81. [PMID: 27885461 DOI: 10.1007/s12272-016-0864-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
369 Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2018;2:1467-78. [PMID: 30556036 DOI: 10.1002/hep4.1267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
370 Laurinavicius AG, Bittencourt MS, Blaha MJ, Nary FC, Kashiwagi NM, Conceiçao RD, Meneghelo RS, Prado RR, Carvalho JA, Nasir K, Blumenthal RS, Santos RD. Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test. QJM 2016;109:531-7. [PMID: 26792853 DOI: 10.1093/qjmed/hcw003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
371 Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400. [PMID: 30355853 DOI: 10.7555/JBR.32.20180045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
372 Delarue J, Lallès J. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. Mol Nutr Food Res 2016;60:147-59. [DOI: 10.1002/mnfr.201500346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
373 Bogumil D, Park SY, Le Marchand L, Haiman CA, Wilkens LR, Boushey CJ, Setiawan VW. High-Quality Diets Are Associated With Reduced Risk of Hepatocellular Carcinoma and Chronic Liver Disease: The Multiethnic Cohort. Hepatol Commun 2019;3:437-47. [PMID: 30859154 DOI: 10.1002/hep4.1313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
374 Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P. A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. Liver Int 2021;41:91-100. [PMID: 32881244 DOI: 10.1111/liv.14650] [Reference Citation Analysis]
375 Hong CW, Marsh A, Wolfson T, Paige J, Dekhordy SF, Schlein AN, Housman E, Deiranieh LH, Li CQ, Wasnik AP, Jang HJ, Dietrich CF, Piscaglia F, Casola G, O'Boyle M, Richman KM, Valasek MA, Andre M, Loomba R, Sirlin CB. Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdom Radiol (NY) 2019;44:54-64. [PMID: 29951900 DOI: 10.1007/s00261-018-1683-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
376 Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They? Cell Metab 2019;29:18-26. [PMID: 30449681 DOI: 10.1016/j.cmet.2018.10.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 19.0] [Reference Citation Analysis]
377 Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Dig Dis Sci 2021;66:2092-100. [PMID: 33782808 DOI: 10.1007/s10620-021-06954-y] [Reference Citation Analysis]
378 Long MT, Pedley A, Massaro JM, Hoffmann U, Esliger DW, Vasan RS, Fox CS, Murabito JM. Hepatic steatosis is associated with lower levels of physical activity measured via accelerometry. Obesity (Silver Spring) 2015;23:1259-66. [PMID: 25959049 DOI: 10.1002/oby.21058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
379 Beacher DR, Ariza AJ, Fishbein MH, Binns HJ. Screening for elevated risk of liver disease in preschool children (aged 2-5 years) being seen for obesity management. SAGE Open Med 2014;2:2050312114555211. [PMID: 26770745 DOI: 10.1177/2050312114555211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
380 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
381 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol 2014; 20(27): 9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
382 Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, Vaidya D. Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol. 2015;13:1686-1693.e2. [PMID: 25592661 DOI: 10.1016/j.cgh.2014.12.033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
383 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
384 Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol 2017;112:755-62. [PMID: 28291240 DOI: 10.1038/ajg.2017.44] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
385 Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Mol Metab 2020;32:1-14. [PMID: 32029220 DOI: 10.1016/j.molmet.2019.11.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
386 Bhatt SP, Misra A, Nigam P, Guleria R, Pasha MA. Phenotype, Body Composition, and Prediction Equations (Indian Fatty Liver Index) for Non-Alcoholic Fatty Liver Disease in Non-Diabetic Asian Indians: A Case-Control Study. PLoS One 2015;10:e0142260. [PMID: 26599361 DOI: 10.1371/journal.pone.0142260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
387 von Wulffen M, Clark PJ, Macdonald GA, Raj AS, Kendall BJ, Powell EE, Jones MP, Holtmann G. Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. Aliment Pharmacol Ther 2016;44:68-77. [PMID: 27189900 DOI: 10.1111/apt.13657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
388 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
389 Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, Carter RE, Roberts LR, Venkatesh SK. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345. [PMID: 30074820 DOI: 10.1259/bjr.20180345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
390 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 23.7] [Reference Citation Analysis]
391 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018; 10(12): 956-965 [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
392 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
393 Hawksworth DJ, Burnett AL. Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems. Sexual Medicine Reviews 2020;8:274-85. [DOI: 10.1016/j.sxmr.2019.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
394 Shen H, Liangpunsakul S. Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006. J Clin Gastroenterol 2016;50:596-601. [PMID: 26905606 DOI: 10.1097/MCG.0000000000000503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
395 Cantoral A, Montoya A, Luna-Villa L, Roldán-Valadez EA, Hernández-Ávila M, Kershenobich D, Perng W, Peterson KE, Hu H, Rivera JA, Téllez-Rojo MM. Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study. BJOG 2020;127:1200-9. [PMID: 32145139 DOI: 10.1111/1471-0528.16199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
396 Naseri E, Xiangyu K, Hu C, Ayaz A, Rahmani MM, Nasim M, Hamdard E, Zahir A, Zhou Q, Wang J, Hou X. Bok-choy promotes growth performance, lipid metabolism and related gene expression in Syrian golden hamsters fed with a high-fat diet. Food Funct 2020;11:2693-703. [PMID: 32182310 DOI: 10.1039/c9fo02975c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Meng X, Li S, Li Y, Gan RY, Li HB. Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics. Nutrients. 2018;10:1457. [PMID: 30297615 DOI: 10.3390/nu10101457] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
398 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1354] [Article Influence: 355.3] [Reference Citation Analysis]
399 Shaheen M, Pan D, Schrode KM, Kermah D, Puri V, Zarrinpar A, Elisha D, Najjar SM, Friedman TC. Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. Hepatol Commun 2021. [PMID: 34558824 DOI: 10.1002/hep4.1775] [Reference Citation Analysis]
400 Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clin Gastroenterol Hepatol 2016;14:1398-411. [PMID: 27155553 DOI: 10.1016/j.cgh.2016.04.036] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 17.4] [Reference Citation Analysis]
401 Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23:48-62. [PMID: 26771116 DOI: 10.1016/j.cmet.2015.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 171] [Article Influence: 39.4] [Reference Citation Analysis]
402 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
403 Sima A, Sporea I, Timar R, Vlad M, Braha A, Popescu A, Nistorescu S, Mare R, Sirli R, Albai A, Albai O, Diaconu L, Sorescu T, Popescu S, Sima L. Non-Invasive Assessment of Liver Steatosis and Fibrosis using Transient Elastography and Controlled Attenuation Parameter in Type 2 Diabetes Patients. Acta Endocrinol (Buchar). 2018;14:394-400. [PMID: 31149289 DOI: 10.4183/aeb.2018.394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Naito H, Yoshikawa-Bando Y, Yuan Y, Hashimoto S, Kitamori K, Yatsuya H, Nakajima T. High-fat and high-cholesterol diet decreases phosphorylated inositol-requiring kinase-1 and inhibits autophagy process in rat liver. Sci Rep 2019;9:12514. [PMID: 31467308 DOI: 10.1038/s41598-019-48973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
405 Hasanain AFA, Mahdy RE, Mahran AMA, Safwat ASM, Mohamed AO, Abdel-Aal SM. Erectile dysfunction in patients with nonalcoholic fatty liver disease. Arab J Gastroenterol 2017;18:21-4. [PMID: 28325476 DOI: 10.1016/j.ajg.2017.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
406 Ehsani MJ, Mahdavi Jafari J, Aliasl J, Kamalinejad M, Gachkar L, Choopani R. Effect of diet based on the principles of Iranian traditional medicine on cirrhosis (a clinical trial). Complement Ther Med 2016;29:35-41. [PMID: 27912954 DOI: 10.1016/j.ctim.2016.09.006] [Reference Citation Analysis]
407 Liu X, Green RM. Endoplasmic reticulum stress and liver diseases. Liver Res. 2019;3:55-64. [PMID: 32670671 DOI: 10.1016/j.livres.2019.01.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
408 Shama S, Liu W. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2020;65:906-10. [PMID: 32036510 DOI: 10.1007/s10620-020-06117-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
409 Engstler AJ, Sellmann C, Jin CJ, Brandt A, Herz K, Priebs J, Bergheim I. Treatment with alpha-galactosylceramide protects mice from early onset of nonalcoholic steatohepatitis: Role of intestinal barrier function. Mol Nutr Food Res 2017;61. [PMID: 28067024 DOI: 10.1002/mnfr.201600985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
410 Tapper EB, Saini SD, Sengupta N. Extensive testing or focused testing of patients with elevated liver enzymes. J Hepatol 2017;66:313-9. [PMID: 27717864 DOI: 10.1016/j.jhep.2016.09.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 3.4] [Reference Citation Analysis]
411 Johnson-davis KL, Dasgupta A. Special Issues in Therapeutic Drug Monitoring in Patients With Uremia, Liver Disease, and in Critically Ill Patients. Clinical Challenges in Therapeutic Drug Monitoring. Elsevier; 2016. pp. 245-60. [DOI: 10.1016/b978-0-12-802025-8.00011-8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
412 Pinheiro PS, Medina HN, Callahan KE, Jones PD, Brown CP, Altekruse SF, McGlynn KA, Kobetz EN. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int 2020;40:1201-10. [PMID: 32087002 DOI: 10.1111/liv.14409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
413 Josan S, Billingsley K, Orduna J, Park JM, Luong R, Yu L, Hurd R, Pfefferbaum A, Spielman D, Mayer D. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 2015;28:1671-1677. [PMID: 26474216 DOI: 10.1002/nbm.3431] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
414 Kallwitz ER, Tayo BO, Kuniholm MH, Cai J, Daviglus M, Cooper RS, Cotler SJ. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clin Gastroenterol Hepatol. 2019;17:2301-2309. [PMID: 30743004 DOI: 10.1016/j.cgh.2019.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
415 Zhang Y, Li C, Li X, Wu C, Zhou H, Lu S, Liu X. Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway. Mol Med Rep 2020;22:2174-82. [PMID: 32705195 DOI: 10.3892/mmr.2020.11309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
416 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
417 Claus M, Antoni C, Hofmann B. Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study. BMC Gastroenterol 2021;21:25. [PMID: 33422007 DOI: 10.1186/s12876-021-01601-2] [Reference Citation Analysis]
418 Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice: Marchesini et al. Hepatology 2016;63:2032-43. [DOI: 10.1002/hep.28392] [Cited by in Crossref: 155] [Cited by in F6Publishing: 142] [Article Influence: 31.0] [Reference Citation Analysis]
419 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
420 Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis. Transplantation. 2019;103:e345-e354. [PMID: 31415032 DOI: 10.1097/tp.0000000000002916] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 19.0] [Reference Citation Analysis]
421 Edula RG, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P, Pyrsopoulos NT. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol 2018;6:241-6. [PMID: 30271734 DOI: 10.14218/JCTH.2017.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
422 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 16.8] [Reference Citation Analysis]
423 Middleton SA, Rajpal N, Cutler L, Mander P, Rioja I, Prinjha RK, Rajpal D, Agarwal P, Kumar V. BET Inhibition Improves NASH and Liver Fibrosis. Sci Rep 2018;8:17257. [PMID: 30467325 DOI: 10.1038/s41598-018-35653-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
424 Walker S. New Medications in the Treatment of Nonalcoholic Steatohepatitis. Hosp Pharm 2018;53:146-7. [PMID: 30147133 DOI: 10.1177/0018578718763098] [Reference Citation Analysis]
425 Tipirneni-Sajja A, Loeffler RB, Hankins JS, Morin C, Hillenbrand CM. Quantitative Susceptibility Mapping Using a Multispectral Autoregressive Moving Average Model to Assess Hepatic Iron Overload. J Magn Reson Imaging 2021;54:721-7. [PMID: 33634923 DOI: 10.1002/jmri.27584] [Reference Citation Analysis]
426 Naran NH, Haagensen M, Crowther NJ. Steatosis in South African women: How much and why? PLoS One 2018;13:e0191388. [PMID: 29351564 DOI: 10.1371/journal.pone.0191388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
427 Lazo M, Bilal U, Perez-Escamilla R. Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep 2015;15:116. [PMID: 26468154 DOI: 10.1007/s11892-015-0674-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
428 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
429 Kim B, Kim M, Jeong JS, Jee S, Park I, Lee B, Chung S, Lim K, Lee Y. Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environmental Research 2019;173:124-34. [DOI: 10.1016/j.envres.2019.03.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
430 Yu D, Shu XO, Xiang YB, Li H, Yang G, Gao YT, Zheng W, Zhang X. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. J Nutr 2014;144:2034-40. [PMID: 25320186 DOI: 10.3945/jn.114.197533] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
431 Burgoon LD, Angrish M, Garcia-Reyero N, Pollesch N, Zupanic A, Perkins E. Predicting the Probability that a Chemical Causes Steatosis Using Adverse Outcome Pathway Bayesian Networks (AOPBNs). Risk Anal 2020;40:512-23. [PMID: 31721239 DOI: 10.1111/risa.13423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
432 Pandit H, Li Y, Zheng Q, Guo W, Yu Y, Li S, Martin RCG. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget 2020;11:2047-60. [PMID: 32547703 DOI: 10.18632/oncotarget.27454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Lee J, Ha J, Jo K, Lim DJ, Lee JM, Chang SA, Kang MI, Cha BY, Kim MH. Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015. Sci Rep. 2018;8:15145. [PMID: 30310098 DOI: 10.1038/s41598-018-32245-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
434 Browning MG, Khoraki J, DeAntonio JH, Mazzini G, Mangino MJ, Siddiqui MS, Wolfe LG, Campos GM. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. Int J Obes (Lond). 2018;42:926-929. [PMID: 29437160 DOI: 10.1038/ijo.2017.309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
435 Yang T, Zhao B, Pei D. Estimation of the Prevalence of Nonalcoholic Fatty Liver Disease in an Adult Population in Northern China Using the Data Mining Approach. Diabetes Metab Syndr Obes 2021;14:3437-45. [PMID: 34349537 DOI: 10.2147/DMSO.S320808] [Reference Citation Analysis]
436 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
437 Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol 2015; 7(11): 1450-1459 [PMID: 26085906 DOI: 10.4254/wjh.v7.i11.1450] [Cited by in Crossref: 116] [Cited by in F6Publishing: 98] [Article Influence: 19.3] [Reference Citation Analysis]
438 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 2017;65:2100-9. [DOI: 10.1002/hep.29068] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
439 Brown JC, Harhay MO, Harhay MN. Nonalcoholic fatty liver disease and mortality among cancer survivors. Cancer Epidemiol 2017;48:104-9. [PMID: 28460349 DOI: 10.1016/j.canep.2017.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
440 Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7:1450-1459. [PMID: 26085906 DOI: 10.4254/wjh.v7.i11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. [PMID: 28775758 DOI: 10.1186/s12986-017-0206-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
442 Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015;19:1-22. [PMID: 25454294 DOI: 10.1016/j.cld.2014.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
443 Moon AM, Watkins SE, Lok AS, Firpi-Morell RJ, Trinh HN, Kupec JT, Schoen C, Neuschwander-Tetri BA, Barritt AS. Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease. Dig Dis 2021;39:247-57. [PMID: 32836224 DOI: 10.1159/000511074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
444 Alazawi W, Bernabe E, Tai D, Janicki T, Kemos P, Samsuddin S, Syn WK, Gillam D, Turner W. Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. PLoS One 2017;12:e0185902. [PMID: 29220367 DOI: 10.1371/journal.pone.0185902] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
445 Haque TR, Barritt AS. Intestinal microbiota in liver disease. Best Practice & Research Clinical Gastroenterology 2016;30:133-42. [DOI: 10.1016/j.bpg.2016.02.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
446 Li J, Wang S, Yao L, Ma P, Chen Z, Han TL, Yuan C, Zhang J, Jiang L, Liu L, Ke D, Li C, Yamahara J, Li Y, Wang J. 6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2019;362:125-135. [PMID: 30408433 DOI: 10.1016/j.taap.2018.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
447 Maturu A, DeWitt P, Kern PA, Rasouli N. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of β-cell function in African American women. Metabolism 2015;64:561-5. [PMID: 25687124 DOI: 10.1016/j.metabol.2015.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
448 Majeed M, Majeed S, Nagabhushanam K, Lawrence L, Mundkur L. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Sci Rep 2020;10:7440. [PMID: 32366854 DOI: 10.1038/s41598-020-64293-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
449 Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int 2016;36:1688-95. [PMID: 27064133 DOI: 10.1111/liv.13144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
450 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
451 Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Res. 2017;6:1630. [PMID: 29093809 DOI: 10.12688/f1000research.12417.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
452 García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Grau M, Muñoz-Yagüe T, Solís-Herruzo JA. NADPH oxidase is implicated in the pathogenesis of oxidative phosphorylation dysfunction in mice fed a high-fat diet. Sci Rep 2016;6:23664. [PMID: 27173483 DOI: 10.1038/srep23664] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
453 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
454 St Pierre TG, House MJ, Bangma SJ, Pang W, Bathgate A, Gan EK, Ayonrinde OT, Bhathal PS, Clouston A, Olynyk JK, Adams LA. Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. PLoS One 2016;11:e0160789. [PMID: 27501242 DOI: 10.1371/journal.pone.0160789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
455 Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378:1096-1106. [PMID: 29562163 DOI: 10.1056/nejmoa1712191] [Cited by in Crossref: 274] [Cited by in F6Publishing: 139] [Article Influence: 91.3] [Reference Citation Analysis]
456 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
457 Zhu JZ, Zhou QY, Wang YM, Dai YN, Zhu J, Yu CH, Li YM. Prevalence of fatty liver disease and the economy in China: A systematic review. World J Gastroenterol 2015; 21(18): 5695-5706 [PMID: 25987797 DOI: 10.3748/wjg.v21.i18.5695] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
458 Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Sex differences in the association of HIV infection with hepatic steatosis. AIDS 2017;31:365-73. [PMID: 27831949 DOI: 10.1097/QAD.0000000000001334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
459 Younossi ZM, Henry L, Bush H, Mishra A. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:1-10. [PMID: 29128049 DOI: 10.1016/j.cld.2017.08.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
460 Browning MG, Pessoa BM, Khoraki J, Campos GM. Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. Curr Obes Rep 2019;8:175-84. [DOI: 10.1007/s13679-019-00334-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
461 Gordon DM, Adeosun SO, Ngwudike SI, Anderson CD, Hall JE, Hinds TD Jr, Stec DE. CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation. Arch Biochem Biophys 2019;672:108072. [PMID: 31422074 DOI: 10.1016/j.abb.2019.108072] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
462 Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015;110:10-4. [PMID: 24890441 DOI: 10.1038/ajg.2014.134] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
463 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
464 Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM. Soybean Oil Is More Obesogenic and Diabetogenic than Coconut Oil and Fructose in Mouse: Potential Role for the Liver. PLoS One 2015;10:e0132672. [PMID: 26200659 DOI: 10.1371/journal.pone.0132672] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
465 Cepero-Donates Y, Lacraz G, Ghobadi F, Rakotoarivelo V, Orkhis S, Mayhue M, Chen YG, Rola-Pleszczynski M, Menendez A, Ilangumaran S, Ramanathan S. Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine 2016;82:102-11. [PMID: 26868085 DOI: 10.1016/j.cyto.2016.01.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
466 Min HK, Mirshahi F, Verdianelli A, Pacana T, Patel V, Park CG, Choi A, Lee JH, Park CB, Ren S, Sanyal AJ. Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G794-803. [PMID: 25747354 DOI: 10.1152/ajpgi.00390.2014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
467 Dillon CF, Weisman MH. US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data. Rheum Dis Clin North Am 2018;44:215-65. [PMID: 29622293 DOI: 10.1016/j.rdc.2018.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
468 Younossi ZM. Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. Hepatology 2018;68:2405-12. [PMID: 30070714 DOI: 10.1002/hep.30125] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
469 Hosick PA, AlAmodi AA, Hankins MW, Stec DE. Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice. Adipocyte 2016;5:1-10. [PMID: 27144091 DOI: 10.1080/21623945.2015.1038443] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
470 Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med. 2014;12:154. [PMID: 25204761 DOI: 10.1186/s12916-014-0154-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
471 Glassner K, Malaty HM, Abraham BP. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:998-1003. [DOI: 10.1097/mib.0000000000001085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
472 O’keefe EL, Dinicolantonio JJ, Patil H, Helzberg JH, Lavie CJ. Lifestyle Choices Fuel Epidemics of Diabetes and Cardiovascular Disease Among Asian Indians. Progress in Cardiovascular Diseases 2016;58:505-13. [DOI: 10.1016/j.pcad.2015.08.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]